This study found that ≥10% FEV1 decline affected ~48% of #alloHSCT recipients and was the strongest predictor of post-transplant mortality. Mortality risk remained elevated even after FEV1 recovery. Read: astctjournal.org/article/S26…
This CIBMTR analysis found no outcome differences among conditioning regimens in pediatric B cell acute lymphoblastic leukemia. MMUD HCT was associated with inferior DFS or OS vs MUD while UCB showed no relapse reduction advantage. Read: astctjournal.org/article/S26…
This study confirms the prognostic value of MRD negativity in #pPCL for the first time. Findings also support that #ASCT can potentially provide response and survival benefits in the era of novel agents. Read: astctjournal.org/article/S26…
This real-world study found that patients with melanoma treated with commercial lifileucel had survival outcomes similar to the pivotal #TIL trial. However only half of patients referred ultimately received therapy. Read the full study: astctjournal.org/article/S26…
This ASTCT expert panel commentary reviews third-party virus-specific T cells for refractory viral infections after #HCT and examines regulatory manufacturing and distribution barriers limiting broader and more equitable access. #VST Read more: astctjournal.org/article/S26…
Transplantation and Cellular Therapy Journal retweeted
Read on updates to the 2012 ASBMT acute #GVHD guidelines, including consensus recommendations on acute GVHD staging and grading, the clinical role of biomarkers and risk-stratification tools and acute GVHD treatment. astctjournal.org/article/S26…
Study found that coronary artery calcification identified during pretransplant evaluation predicted non-relapse mortality in patients receiving PTCy. Among elderly patients without known coronary artery disease, it was associated with inferior survival. ow.ly/p4rP50ZPM6U
Read on updates to the 2012 ASBMT acute #GVHD guidelines, including consensus recommendations on acute GVHD staging and grading, the clinical role of biomarkers and risk-stratification tools and acute GVHD treatment. astctjournal.org/article/S26…
This real-world analysis found that prophylactic anakinra did not reduce grade ≥3 #CART associated neurotoxicity syndrome. No survival or response rate differences observed with anakinra prophylaxis. Read: astctjournal.org/article/S26…
This study provides first evidence linking Lnc-BRMS1L-4 and ZEB1-AS1 to acute lymphoblastic leukemia and clinical features. Read the full study: astctjournal.org/article/S26…
The September issue of 'Transplantation and Cellular Therapy,' is now available online: astctjournal.org/current
@ELShematology
This study found a 6.8% 10-year incidence of non-cutaneous secondary malignancies after #HCT confirming their impact on late nonrelapse mortality. PTCy-based #GVHD prophylaxis was not associated with increased solid tumor risk. Read: astctjournal.org/article/S26…
This analysis highlights the substantial physical mental and emotional burden of chronic #GVHD on patients and caregivers. Posts also described inability to work high treatment costs and distinct challenges for caregivers of pediatric and adult patients. astctjournal.org/article/S26…
This GATMO-TC experience found 3-year overall survival exceeded 85% after haploidentical HCT for severe aplastic anemia and exceeded 90% with upfront haplo-HCT. Graft failure occurred in 4.5% of patients. Read more: astctjournal.org/article/S26…
This two-center study found that earlier defibrotide initiation within 2 days of SOS/VOD diagnosis was associated with improved survival after #alloHCT in adults. Dialysis requirement was associated with poorer outcomes. Read more: astctjournal.org/article/S26…
This long-term follow-up study found that CD19 #CART therapy yielded sustained remissions in R/R B-NHL. High tumor Ki-67 was a poor prognostic factor and was associated with limited CAR-T cell expansion, especially CD8+ cells. Read: astctjournal.org/article/S26…
This systematic review and meta-analysis found that primary ovarian insufficiency and amenorrhea affect 72% and 70% of female #alloHCT survivors. Genital chronic #GVHD occurs in 36% sexual dysfunction in 42% and post-transplant pregnancy in 12%. Read: astctjournal.org/article/S26…
This review highlights implementation challenges for value-based contracts in cell and gene therapies. Outcome selection and data tracking remain key barriers while treatment center workflows can support consistent reliable outcome tracking. Read: astctjournal.org/article/S26…
This study highlights that early #HSCT for infantile osteopetrosis can lead to better quality of life. Genetic testing is essential as certain mutations are not indicated for HSCT. Read the full study: astctjournal.org/article/S26…
Dose adjustment may be necessary in post #HSCT gilteritinib maintenance therapy. Gilteritinib can be a beneficial maintenance treatment for relapsed or refractory FLT3-mutated acute myeloblastic leukemia after HSCT. Read the full study: astctjournal.org/article/S26…
